S-adenozylmetionín – SAMe


  1. A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia.
  2. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer’s disease: a placebo-controlled pilot study.
  3. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer’s disease: a 1-year, open-label pilot study with an 16-month caregiver extension.
  4. S-Adenosylmethionine (Ademetionine) in Psychiatric Disorders: Historical Perspective and Current Status.
  5. Bottiglieri T, et al. Homocysteine, folate, methylation, and monoamine metabolism in depressionJ Neurol Neurosurg Psychiatry. (2000)
  6. Loehrer FM, et al. Influence of oral S-adenosylmethionine on plasma 5-methyltetrahydrofolate, S-adenosylhomocysteine, homocysteine and methionine in healthy humansJ Pharmacol Exp Ther. (1997)
  7. Thompson MA, et al. Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trialJ Altern Complement Med. (2009)
  8. Struys EA, et al. Determination of S-adenosylmethionine and S-adenosylhomocysteine in plasma and cerebrospinal fluid by stable-isotope dilution tandem mass spectrometryClin Chem. (2000)
  9. Bell KM, et al. S-adenosylmethionine blood levels in major depression: changes with drug treatmentActa Neurol Scand Suppl. (1994)
  10. Shippy RA, et al. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDSBMC Psychiatry. (2004)
  11. S-Adenosylmethionine Levels in the Diagnosis of Pneumocystis carinii Pneumonia in Patients with HIV Infection.
  12. Bottiglieri T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionineJ Neurol Neurosurg Psychiatry. (1990)
  13. Poirier LA, et al. Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathyMetabolism. (2001)
  14. Maj M, Zizolfi S, Del Vecchio M. Blood levels of S-adenosylmethionine in unmedicated schizophrenic and depressive patientsNeuropsychobiology. (1981)
  15. Andreoli VM, Maffei F, Tonon GC. S-adenosyl-L-methionine (SAMe) blood levels in schizophrenia and depressionMonogr Gesamtgeb Psychiatr Psychiatry Ser. (1978)
  16. Strous RD, et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophreniaEur Neuropsychopharmacol. (2009)
  17. Stabler SP, et al. Elevated serum S-adenosylhomocysteine in cobalamin-deficient elderly and response to treatmentAm J Clin Nutr. (2006)
  18. Poirier LA, et al. Blood determinations of S-adenosylmethionine, S-adenosylhomocysteine, and homocysteine: correlations with dietCancer Epidemiol Biomarkers Prev. (2001)
  19. Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamicsAm J Med. (1987)
  20. Silveri MM, et al. S-adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjectsBiol Psychiatry. (2003)
  21. Dunne JB, et al. Evidence that S-adenosyl-L-methionine diastereoisomers may reduce ischaemia-reperfusion injury by interacting with purinoceptors in isolated rat liverBr J Pharmacol. (1998)
  22. Hoffman JL. Chromatographic analysis of the chiral and covalent instability of S-adenosyl-L-methionineBiochemistry. (1986)
  23. Lee S, et al. Steric Course of the Methyl Transfer from AdoMet to S-Farnesyl-3-thiopropionate by G-Protein MethyltransferaseJ Org Chem. (1998)
  24. Kealey JT, et al. Stereochemistry of methyl transfer catalyzed by tRNA (m5U54)-methyltransferase–evidence for a single displacement mechanismNucleic Acids Res. (1991)
  25. Woodard RW, et al. Stereochemical course of the transmethylation catalyzed by catechol O-methyltransferaseJ Biol Chem. (1980)
  26. Borchardt RT, Wu YS. Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 5. Role of the asymmetric sulfonium pole in the enzymatic binding of S-adenosyl-L-methionineJ Med Chem. (1976)
  27. Najm WI, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. {ISRCTN36233495}BMC Musculoskelet Disord. (2004)
  28. McMillan JM, Walle UK, Walle T. S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytesJ Pharm Pharmacol. (2005)
  29. Yang J, et al. Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteersClin Ther. (2009)
  30. Giulidori P, et al. Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteersEur J Clin Pharmacol. (1984)
  31. Agrimi G, et al. Identification of the human mitochondrial S-adenosylmethionine transporter: bacterial expression, reconstitution, functional characterization and tissue distributionBiochem J. (2004)
  32. Dridi L, Ahmed Ouameur A, Ouellette M. High affinity S-Adenosylmethionine plasma membrane transporter of Leishmania is a member of the folate biopterin transporter (FBT) familyJ Biol Chem. (2010)
  33. Horne DW, Holloway RS, Wagner C. Transport of S-adenosylmethionine in isolated rat liver mitochondriaArch Biochem Biophys. (1997)
  34. Williams AC, Ramsden DB. Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseasesMed Hypotheses. (2005)
  35. Pavia J, et al. Effect of S-adenosyl methionine on muscarinic receptors in young ratsLife Sci. (1997)
  36. Muccioli G, et al. Effect of S-adenosyl-L-methionine on brain muscarinic receptors of aged ratsEur J Pharmacol. (1992)
  37. Chan A, et al. Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: critical role of S-adenosyl methionineJ Nutr Health Aging. (2008)
  38. Shea TB, Chan A. S-adenosyl methionine: a natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer’s diseaseJ Alzheimers Dis. (2008)
  39. Fava M, et al. Folate, vitamin B12, and homocysteine in major depressive disorderAm J Psychiatry. (1997)
  40. Alpert JE, et al. Nutrition and depression: focus on folateNutrition. (2000)
  41. Bottiglieri T, et al. Transmethylation in depressionAla J Med Sci. (1988)
  42. Matthysse S, Baldessarini RJ. S-adenosylmethionine and catechol-O-methyl-transferase in schizophreniaAm J Psychiatry. (1972)
  43. Tolbert LC. MAT kinetics in affective disorders and schizophrenia. An accountAla J Med Sci. (1988)
  44. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studiesActa Neurol Scand Suppl. (1994)
  45. Saletu-Zyhlarz GM, et al. Visualizing central effects of S-adenosyl-L-methionine (SAMe), a natural molecule with antidepressant properties, by pharmaco-EEG mappingInt J Neuropsychopharmacol. (2002)
  46. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence.
  47. Fava M, et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methioninePsychiatry Res. (1995)
  48. Berlanga C, et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipraminePsychiatry Res. (1992)
  49. Papakostas GI, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trialAm J Psychiatry. (2010)
  50. Fleisch SB, Travis MJ, Ryan ND. Discrepancy in response and remission rates for SAMe-treated patients in a double-blind, randomized clinical trialAm J Psychiatry. (2010)
  51. Alpert JE, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxineJ Clin Psychopharmacol. (2004)
  52. Sarris J1, et al. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of responseJ Affect Disord. (2014)
  53. Strous RD, et al. Aggressive behavior in schizophrenia is associated with the low enzyme activity COMT polymorphism: a replication studyAm J Med Genet B Neuropsychiatr Genet. (2003)
  54. Strous RD, et al. Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behaviorPsychiatry Res. (1997)
  55. Di Rocco A, et al. S-Adenosyl-Methionine improves depression in patients with Parkinson’s disease in an open-label clinical trialMov Disord. (2000)
  56. Levkovitz Y, et al. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorderJ Affect Disord. (2012)
  57. Arnold O, et al. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometryEur Neuropsychopharmacol. (2005)
  58. Spijkerman AM, et al. S-adenosylmethionine and 5-methyltetrahydrofolate are associated with endothelial function after controlling for confounding by homocysteine: the Hoorn StudyArterioscler Thromb Vasc Biol. (2005)
  59. Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease.
  60. Mischoulon D, et al. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorderJ Clin Psychiatry. (2012)
  61. Gören JL, et al. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humansPharmacotherapy. (2004)
  62. Tavoni A, et al. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover studyAm J Med. (1987)
  63. Volkmann H, et al. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgiaScand J Rheumatol. (1997)
  64. Jacobsen S, Danneskiold-Samsøe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluationScand J Rheumatol. (1991)
  65. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal painBest Pract Res Clin Rheumatol. (2007)
  66. Kalhan SC, et al. Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionineClin Sci (Lond). (2011)
  67. Loguercio C, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver diseaseAlcohol Alcohol. (1994)
  68. Chawla RK, et al. Plasma cysteine, cystine, and glutathione in cirrhosisGastroenterology. (1984)
  69. Yuan L, Kaplowitz N. Glutathione in liver diseases and hepatotoxicityMol Aspects Med. (2009)
  70. Mato JM, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trialJ Hepatol. (1999)
  71. Santini D, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injuryAnticancer Res. (2003)
  72. Binder T, et al. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancyJ Perinat Med. (2006)
  73. Roncaglia N, et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasisBJOG. (2004)
  74. Nicastri PL, et al. A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancyBr J Obstet Gynaecol. (1998)
  75. Floreani A, et al. S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trialEur J Obstet Gynecol Reprod Biol. (1996)
  76. Ribalta J, et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative resultsHepatology. (1991)
  77. Duong FH, et al. S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitroHepatology. (2006)
  78. Duong FH, et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2AGastroenterology. (2004)
  79. Duong FH, et al. Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1J Virol. (2005)
  80. Filipowicz M, et al. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponsePLoS One. (2010)
  81. Feld JJ, et al. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonrespondersGastroenterology. (2011)
  82. Medici V, et al. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trialAlcohol Clin Exp Res. (2011)
  83. Caruso I, Pietrogrande V. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint diseaseAm J Med. (1987)
  84. Witte S, Lasek R, Victor N. Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritisOrthopade. (2002)
  85. Soeken KL, et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritisJ Fam Pract. (2002)
  86. di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studiesAm J Med. (1987)
  87. Kim J, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patientsClin Ther. (2009)
  88. Papadopoulos V, et al. Effects of the transmethylation inhibitor S-adenosyl-homocysteine and of the methyl donor S-adenosyl-methionine on rat Leydig cell function in vitroJ Steroid Biochem. (1987)
  89. Manteuffel-Cymborowska M, Chmurzynska W, Grzelakowska-Sztabert B. Tissue-specific effects of testosterone on S-adenosylmethionine formation and utilization in the mouseBiochim Biophys Acta. (1992)
  90. Heljasvaara R, et al. Transgenic mice overexpressing ornithine and S-adenosylmethionine decarboxylases maintain a physiological polyamine homoeostasis in their tissuesBiochem J. (1997)
  91. Crozat A, et al. Comparison of androgen regulation of ornithine decarboxylase and S-adenosylmethionine decarboxylase gene expression in rodent kidney and accessory sex organsEndocrinology. (1992)
  92. Fjösne HE, Strand H, Sunde A. Dose-dependent induction of ornithine decarboxylase and S-adenosyl-methionine decarboxylase activity by testosterone in the accessory sex organs of male ratsProstate. (1992)
  93. de las Heras MA, Calandra RS. S-adenosyl-L-methionine decarboxylase activity in the rat epididymis: ontogeny and androgenic controlJ Androl. (1991)
  94. Müller T, Fowler B, Kuhn W. Levodopa intake increases plasma levels of S-adenosylmethionine in treated patients with Parkinson diseaseClin Neuropharmacol. (2005)
  95. Kagan BL, et al. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trialAm J Psychiatry. (1990)